surpass 4 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial SURPASS-4: Tirzepatide slows kidney disease

Recomenda-se tomar 2 cpsulas s 10h e 2 cpsulas s 16h

31% of GLP-1 users drank less alcohol in the past year

Evidence-based dietary, hydration, meal-timing, and supplement strategies to reduce diarrhea caused by Wegovy (semaglutide 2.4 mg), with specific foods to

Maryland Medical Clinic offers doctor-led weight loss treatments designed for effective results

Clear expectations around recovery, potential complications and long term adjustments can help people feel more prepared and supported throughout their care journey.

Evidence also continues to support integrating minimally invasive ESG solutions such as EndoZip into bariatric practice